Beyond Biotech - the podcast from Labiotech

Labiotech
  • 3.3 (3)
  • Tech News
  • Updated Weekly

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

  1. 2d ago

    Theialife’s race to bring a childhood myopia treatment to market

    By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision loss later in life. Children face a narrow window in which to intervene, while the eye is still growing, before those structural changes become permanent. Yet despite the scale of the problem, there is still no FDA-approved drug that slows myopia progression in children, a gap underscored just last month when the FDA declined to approve an atropine eye drop for the same use. My guest today is Thomas Ruggia, President and CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite. Tom joins Theialife after 25 years in ophthalmology leadership, including roles at Johnson & Johnson, Alcon, Novartis, and most recently as CEO of Samsara Vision. We'll talk mechanism, evidence, and the road to Phase 3. 01:49 Meet Thomas Ruggia 06:50 How progressive myopia develops in children and why it's misunderstood 15:55 ND10's mechanism of action 19:51 20 years of Danish compassionate-use data vs. a randomised trial 26:44 Why no FDA-approved pharmacologic therapy exists yet 37:57 Theialife's pipeline beyond myopia Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Innovation in ophthalmology: How biotechs are reshaping the treatment of eye diseasesCan gene therapy treat vision loss?Europe’s Ophthalmology Scene Stays Hot for Biotech Funding

  2. Sep 18

    The best biotech conversations you missed this summer

    Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months. We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of Step Pharma and Gene Mack of Gain Therapeutics, and the unlikely paths that got them there. We'll dig into the science of nonsense mutations with Nerissa Kreher of Alltrna, circular RNA with Lu Gao of Therorna, and a cancer target hiding in human genetics. And we'll close with what these leaders think success actually looks like, years from now. So sit back, and let's revisit some of our favourite moments from the summer. 02:32 Solving the delivery problem08:39 Founder journeys15:13 Platform science24:41 Business, money, and geopolitics32:28 Looking aheadInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Episode 204: The first PROTAC is here. What comes next in protein degradation?Episode 205: Turning cancer cell dependencies into targeted therapiesEpisode 208: Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson'sEpisode 209: Why Western pharma is sleeping on China's circular RNA revolutionEpisode 211: Beyond biology: Nanobiotix's physics-first approach to cancerEpisode 213: How Evox Therapeutics is targeting CNS diseases with exosomesEpisode 214: Rewriting the rules of genetic medicine with tRNA therapeutics

  3. Sep 11

    Rewriting the rules of genetic medicine with tRNA therapeutics

    Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic disease diagnoses, and asks whether a single engineered molecule could address it across many conditions at once. My guest today is Dr. Nerissa Kreher, Chief Medical Officer of Alltrna. Nerissa brings two decades of rare disease drug development experience, including CMO roles at Entrada Therapeutics, Tiburio Therapeutics, and AVROBIO, to the task of turning that platform thesis into an actual clinical program. We'll talk translation, trial design, and what it takes to bring the first engineered tRNA therapy into the clinic. 02:45 Meet Nerissa Kreher and Alltrna's tRNA platform07:29 Gene-by-gene versus mutation-by-mutation drug development12:08 What nonsense mutations are and why they matter15:55 Phase 1 trial approval in Australia19:49 What basket trials are and FDA receptiveness27:27 Where Alltrna could be in five yearsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Beyond Biotech - Episode 66: treating rare diseases with tRNAWill tRNA therapy be the next big thing in genetic disease treatment?Pharma giants pull back on AAV research: what’s next for the gene therapy space?

  4. Sep 4

    How Evox Therapeutics is targeting CNS diseases with exosomes

    Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change. The recent FDA approval of a brain-penetrant enzyme therapy for Hunter syndrome showed that biologics can cross that barrier and work. The next question is whether gene editing can do the same. My guest today is Dr. Per Lundin, Co-Founder and CEO of Evox Therapeutics, a UK biotech using engineered exosomes to deliver genetic medicines directly into the brain. Evox is now extending that platform from RNA and biologics into gene editing, targeting the genetic drivers of diseases like Huntington's and ALS, where treatment options remain extremely limited. Per also brings a background as a European Patent Attorney and repeat biotech founder. We'll talk delivery, pipeline, and what a commercially scalable genetic medicine for the brain might actually look like. 02:45 Per Lundin's background and Evox's platform09:38 Denali's Hunter syndrome approval and its significance14:58 Targeting MSH3 to treat Huntington's disease20:03 What commercially scalable genetic medicine requires22:13 Evox's dominant IP position in exosome delivery27:34 What success could mean for patients in ten yearsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1BSix exosome therapy companies driving development in the fieldExtracellular vesicles: a growing pipeline still searching for validation

  5. Aug 28

    BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech

    Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering. For the first time and in response to strong sector demand and growing interest, BIOSPAIN moves to an annual format. Hosted this year in vibrant Bilbao in Spain’s dynamic Basque Country, the event runs from 29 September to 1 October at the Bilbao Exhibition Centre. In this episode we explore the BIOSPAIN program, the partnering opportunities on offer, the new Talent Day on the final day, and all the practical and logistical details for attendees.  04:02 Why BIOSPAIN is moving to an annual format 05:17 Bilbao and the Basque country09:44 BIOSPAIN 2026: four program tracks13:47 One-on-one partnering 16:10 International participation and a growing Latin American presence 22:27 Talent Day: BIOSPAIN's dedicated biotech job fair 27:48 Ticket options, exhibiting, and sponsorship opportunitiesThis episode is presented with the support of Asebio and BIOSPAIN. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Pharma in Spain: why global investors and innovators are moving inPractical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next stepEpisode 165 - BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year

  6. Aug 21

    Beyond biology: Nanobiotix's physics-first approach to cancer

    What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic. Nanobiotix is a Paris-based biotech pioneering what they call physics-based nanomedicine. Their lead asset is a radioenhancer made of hafnium oxide nanoparticles, designed to be injected directly into a tumor and amplify the destructive power of radiotherapy from within — without increasing damage to surrounding healthy tissue. It is currently in Phase 3 trials in head and neck cancer. But that's only half the story. The company's Nanoprimer platform is now emerging as a potential new engine for growth — with the promise of making an entirely new class of genetic medicines work better. 02:47 Meet Laurent Lévy06:04 What physics offers that biology cannot 11:12 How JNJ-1900 (NBTXR3) works 15:14 The immune effect 18:16 Pipeline milestones ahead20:56 The Curadigm Nanoprimer platform 25:32 The oversubscribed €85 million raiseInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III ResultsGet to know 15 of the best biotech companies in ParisEight nanotechnology companies to watch out for

  7. Aug 14

    How Cancer Research Horizons is building the future of childhood cancer medicines

    Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive. Today's guest is working to change that, and much more besides.  Tony Hickson is Chief Business Officer for Cancer Research Horizons, Cancer Research UK's innovation engine, responsible for turning early-stage science into new treatments, diagnostics, and start-up companies. Tony's career spans big pharma, university tech transfer, and now the translational front line of cancer research, and he's helped build dozens of spinouts along the way. We'll talk about why charity and pharma need each other more than ever, and about C-Further, a bold new push to finally build medicines made for children, not borrowed from adults. 01:25 Meet Tony Hickson05:21 What sets Cancer Research Horizons apart from tech transfer offices12:17 Myrix Bio's exit to Novartis, a standout story15:54 Can patient benefit and commercial success align28:53 Inside C-Further's first two therapeutic programs41:19 How researchers and partners can get involvedInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Episode 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, TurbineCancer Research UK Deploys €700M to Foster Oncology StartupsCancer vaccines: 11 biotechs to keep an eye out for

  8. Aug 7

    Why Western pharma is sleeping on China's circular RNA revolution

    RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA. CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be the most advanced independent circRNA platform in the world — and with barely a single line of English-language press coverage, until now. My guest today is Dr. Lu Gao, CEO of Therorna Inc., a clinical-stage biotech headquartered in Beijing and Shanghai. The company recently presented three posters at ASGCT in Boston, and their lead program has just entered a first-in-human trial. We're going to talk about the science, the clinical strategy, and why Western pharma hasn't paid enough attention to what's being built in China. 01:33 Meet Lu Gao and Therorna 09:29 How Therorna's approach differs 15:42 How TI-0032 reprograms T cells in the body 21:22 Off-the-shelf and re-dosable: what it means for patients 24:38 Why no Chinese biotech has landed a major in vivo deal 31:27 What a successful US IND clearance would mean Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  The therapeutic potential of circular RNA: Could it soon trump mRNA technology?mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeuticsTherorna funding to accelerate circRNA-based platform

See All (216)

Ratings & Reviews

3.3
out of 5
3 Ratings

About

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Information

You Might Also Like